Literature DB >> 22762027

Advances and application of radioimmunotherapy in non-Hodgkin lymphoma.

Patrick L Stevens1, Olalekan Oluwole, Nishitha Reddy.   

Abstract

The activity of radio-immuno conjugate in Non-Hodgkin Lymphoma (NHL) has resulted in FDA approval of two antibodies, Y(90) Ibritumomab tiuxetan and I(131) tositumomab. Both these agents target CD20, a receptor widely expressed in B-Cell NHL. These immunoconjugates deliver their radioactive payload to the malignant clone in the bone marrow and lymph node. Their use has been associated with modest improvement in survival end points among several lymphoma histologies. The promising effect on disease control as well as their efficacy in disease relapse is encouraging in low grade lymphoma. Radioimmunotherapy (RIT) is increasingly being explored in the setting of consolidation as well as conditioning regimens prior to stem cell transplantation. Here, we summarize the clinical use, complications and future applications of RIT in NHL.

Entities:  

Keywords:  CD20 target; Radioimmunotherapy; non-Hodgkin lymphoma; stem cell transplantation

Year:  2012        PMID： 22762027      PMCID： PMC3384399     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN： 2160-1992


  42 in total

1.  Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.

Authors:  Wolfgang A Bethge; Thoralf Lange; Christoph Meisner; Stephanie von Harsdorf; Martin Bornhaeuser; Birgit Federmann; Michael Stadler; Lutz Uharek; Matthias Stelljes; Stefan Knop; Gerald Wulf; Rudolf Trenschel; Vladan Vucinic; Helmut Dittmann; Christoph Faul; Wichard Vogel; Lothar Kanz; Donald Bunjes
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

2.  Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.

Authors:  Scott H Olejniczak; Francisco J Hernandez-Ilizaliturri; James L Clements; Myron S Czuczman
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

3.  Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.

Authors:  Pier Luigi Zinzani; Letizia Gandolfi; Vittorio Stefoni; Stefano Fanti; Mariapaola Fina; Cinzia Pellegrini; Gian Carlo Montini; Enrico Derenzini; Alessandro Broccoli; Lisa Argnani; Stefano Pileri; Michele Baccarani
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-08

4.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

Authors:  M S Kaminski; J Estes; K R Zasadny; I R Francis; C W Ross; M Tuck; D Regan; S Fisher; J Gutierrez; S Kroll; R Stagg; G Tidmarsh; R L Wahl
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

5.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Authors:  P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

6.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Authors:  Thomas E Witzig; Ian W Flinn; Leo I Gordon; Christos Emmanouilides; Myron S Czuczman; Mansoor N Saleh; Larry Cripe; Gregory Wiseman; Teresa Olejnik; Pratik S Multani; Christine A White
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

Authors:  Amrita Krishnan; Auayporn Nademanee; Henry C Fung; Andrew A Raubitschek; Arturo Molina; Dave Yamauchi; Roberto Rodriguez; Ricardo T Spielberger; Peter Falk; Joycelynne M Palmer; Stephen J Forman
Journal:  J Clin Oncol       Date:  2007-11-19       Impact factor: 44.544

8.  High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

Authors:  Ajay K Gopal; Theodore A Gooley; David G Maloney; Stephen H Petersdorf; Janet F Eary; Joseph G Rajendran; Sharon A Bush; Lawrence D Durack; Jane Golden; Paul J Martin; Dana C Matthews; Frederick R Appelbaum; Irwin D Bernstein; Oliver W Press
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

9.  Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.

Authors:  Myron S Czuczman; Christos Emmanouilides; Mohamed Darif; Thomas E Witzig; Leo I Gordon; Stephen Revell; Katie Vo; Arturo Molina
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

Authors:  P L Zinzani; M Tani; S Fanti; V Stefoni; G Musuraca; P Castellucci; E Marchi; M Farsad; M Fina; C Pellegrini; L Alinari; E Derenzini; A de Vivo; F Bacci; S Pileri; M Baccarani
Journal:  Ann Oncol       Date:  2008-02-25       Impact factor: 32.976
View more
  3 in total

1.  Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy?

Authors:  Koichiro Kaneko; Ilseung Choi; Makoto Nakagawa; Kenji Shinozaki; Naokuni Uike
Journal:  Eur Radiol       Date:  2014-08-12       Impact factor: 5.315

2.  A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Authors:  A Dispenzieri; A D'Souza; M A Gertz; K Laumann; G Wiseman; M Q Lacy; B LaPlant; F Buadi; S R Hayman; S K Kumar; D Dingli; W J Hogan; S M Ansell; D A Gastineau; D J Inwards; I N Micallef; L F Porrata; P B Johnston; M R Litzow; T E Witzig
Journal:  Bone Marrow Transplant       Date:  2017-09-04       Impact factor: 5.483

3.  Novel target for peptide-based imaging and treatment of brain tumors.

Authors:  Maija Hyvönen; Juulia Enbäck; Tuulia Huhtala; Johanna Lammi; Harri Sihto; Janne Weisell; Heikki Joensuu; Katri Rosenthal-Aizman; Samir El-Andaloussi; Ulo Langel; Ale Närvänen; Gabriele Bergers; Pirjo Laakkonen
Journal:  Mol Cancer Ther       Date:  2014-02-03       Impact factor: 6.261
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.